PDCD1LG2 and Hodgkins lymphoma: Recently in classic Hodgkin lymphoma, a 9p24.1 amplification involving CD274 (PD-L1) and PDCD1LG2 (PD-L2) was shown to predict response to nivolumab outcomes33.